Nordestgaard, Børge G.
Nicholls, Stephen J.
Langsted, Anne
Ray, Kausik K.
Tybjærg-Hansen, Anne
Article History
First Online: 8 February 2018
Competing interests
: B.G.N. is a consultant for Amgen, AstraZeneca, Denka Seiken, Dezima Pharma, Ionis Pharmaceuticals, Kowa, Merck, Regeneron Pharmaceuticals, and Sanofi. S.J.N. has received research funding from Amgen, Anthera Pharmaceuticals, AstraZeneca, Cerenis Therapeutics, Eli Lilly, InfraReDx, LipoScience, Novartis, Regeneron Pharmaceuticals, Resverlogix, Roche, Sanofi, and The Medicines Company, and is a consultant for Anthera Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion Therapeutics, Merck, Omthera Pharmaceuticals, Regeneron Pharmaceuticals, Resverlogix, Sanofi, and Takeda. K.K.R. has received research funding from Amgen, Merck, Pfizer, Regeneron, and Sanofi, and is a consultant for AbbVie, Algorithm, Amgen, AstraZeneca, Boehringer Ingelheim, Cerenis Therapeutics, Cipla, Eli Lilly, Esperion, Ionis Pharmaceuticals, Kowa, Merck, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Takeda, and The Medicines Company. The other authors declare no competing interests.